Report Highlights
-
The overall central nervous system therapeutic drug market is valued at an estimated $78 billion in 2010. This market will experience a nominal reduction in the early portion of the forecast period, and then slowly rise at a compound annual growth rate (CAGR) of 0.7% to reach nearly $81.8 billion by 2015.
-
By a narrow margin, psychiatry is the largest segment within the central nervous system market, driven by a number of billion–dollar–plus therapies. The market is worth an estimated $20.5 billion in 2010 and will experience a –12.1% compound annual growth rate (CAGR) through 2015, to a level of $10.8 billion.
-
Treatment for depression recorded sales of nearly $16 billion in 2010. Large therapeutic drugs, including Lexapro and Cymbalta, comprise a high concentration of this segment. Driven by patent expiration for Lexapro and other drugs, this segment will shrink to $9.7 billion by 2015, a compound annual growth rate (CAGR) of –9.4%.
INTRODUCTION
- Established companies in the industry shall benefit from the contents, including corporate strategy, sales and marketing, business development, and R&D.
- Emerging biotechnology players in the segment must understand specific opportunities for out–licensing, originating from the elements of differentiation of their therapeutic drug as compared to leading, competitive, and emerging therapies. As well, market forecasts can support investment, provided a thorough and detailed substantiation is provided for the market forecast, as is found in this study.
- Investment firms evaluating candidates for venture capital or hedged investments will gain insights as to the opportunity and risks that are being encountered in the industry, in a product and company specific analysis.
- Equity analysts are provided detailed forecasts for the next 5 years, substantiated by quantitative analysis that can support further analysis to product and company forecasts over the short and long term.
ANALYST CREDENTIALS
Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy, where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early- and mid-stage drug development.
- Examine BCC’s complete catalog of Market Research Reports and place direct orders
- Subscribe to any of BCC’s many industry newsletters
- Read announcements of recently published reports and newly launched newsletters
- Register for BCC’s well-known conferences
- Request additional information on any BCC product
- Take advantage of special offers
Recent Reports
Drugs and Diagnostics for Hematological Disorders: Global Markets
The global market for drugs and diagnostics for hematological disorders is expected to grow from $131.2 billion in 2024 and is projected to reach $189.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.6% during the forecast period of 2024 to 2029.
Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets
The global market for gastrointestinal (GI) therapeutics and diagnostics is expected to grow from $86.0 billion in 2023 and projected to reach $122.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.3% during the forecast period of 2023 to 2028.
Global Markets and Technologies for Advanced Drug Delivery Systems
The global market for advanced drug delivery systems is expected to increase from $262.6 billion in 2023 to $359.1 billion by the end of 2028, with a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2023-2028.
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.
Chagas Disease: American trypanosomiasis Market
The report provides detailed coverage of the Chagas Disease market. It analyzes the market trends and epidemiology of CD, and the regional markets of CD. It highlights the current market for CD and gives a detailed analysis of the competitive environment. The report depicts the complete scenario of Chagas Disease, types of parasites that cause human African trypanosomiasis (HAT) and its presence in various regions of the world.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More